Moderna, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

21 Feb 2025

MRNA

10-K: Moderna's 2024 10-K Filing: Focus on Growth, Efficiency, and Pipeline Advancement

Moderna's 2024 10-K filing highlights a year of transition, marked by commercial challenges, strategic portfolio prioritization, and advancements in its mRNA platform and pipeline.

NASDAQ

23 Feb 2024

MRNA

Moderna, INC

10-K: Moderna's 2023 10-K Filing: Transitioning to Endemic Market and Expanding Pipeline

Moderna's 2023 annual report highlights a shift to an endemic COVID-19 vaccine market, significant manufacturing resizing, and advancements in its diverse mRNA pipeline.